SJP 0129 - Senju Pharmaceutical

Drug Profile

SJP 0129 - Senju Pharmaceutical

Alternative Names: SJP-0129

Latest Information Update: 05 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Senju Pharmaceutical
  • Class Vascular disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Patent ductus arteriosus

Most Recent Events

  • 28 Jul 2016 Senju Pharmaceuticals completes a phase-III trial in Patent ductus arteriosus (In neonates) in Japan (IV) (UMIN000018226)
  • 07 Jul 2015 Clinical trials in Patent ductus arteriosus in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top